Abstract
Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have